Drug
Wockhardt’s Zaynich antibiotic clears FDA and CDSCO approval
Zaynich is an oxazolidinone-class antibiotic indicated for complicated skin, soft tissue and dental infections, including refractory odontogenic cases. Recommended dose is 600 mg orally twice daily. It received CDSCO approval on May 27, 2026 and FDA approval in June 2026, and is now marketed in India, providing a new option against resistant Gram-positive oral pathogens.
Source: Biotecnika
21 Nov 2026 · DentalSync AI — global BDS career platform